NASDAQ: PVLAPalvella Therapeutics Inc Stock
$110.12-6.39 (-5.48%)
Updated Jun 16, 2026
PVLA Price
$110.12
Fair Value Price
$5.10
Market Cap
$1.58B
52 Week Low
$20.20
52 Week High
$151.18
P/E
-26.41x
P/B
6.8x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$49.30M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.14
Operating Cash Flow
-$29M
Beta
0.84
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
PVLA Overview
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PVLA's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
PVLA
Ranked#382 of 462
Ranked#382 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $226.88 | A | |
| $52.10 | A | |
| $16.22 | A |
Be the first to know about important PVLA news, forecast changes, insider trades & much more!
PVLA News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PVLA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PVLA ($110.12) is overvalued by 2,060.43% relative to our estimate of its Fair Value price of $5.10 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
PVLA ($110.12) is not significantly undervalued (2,060.43%) relative to our estimate of its Fair Value price of $5.10 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
PVLA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PVLA due diligence checks available for Premium users.
Valuation
PVLA fair value
Fair Value of PVLA stock based on Discounted Cash Flow (DCF)
Price
$110.12
Fair Value
$5.10
Overvalued by
2,060.43%
PVLA ($110.12) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PVLA ($110.12) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PVLA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PVLA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-26.41x
Industry
16.03x
Market
13.25x
PVLA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.8x
Industry
4.86x
PVLA is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PVLA's financial health
Profit margin
Revenue
$0.0
Net Income
-$15.8M
Profit Margin
0%
PVLA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$263.8M
Liabilities
$31.4M
Debt to equity
0.14
PVLA's short-term assets ($263.23M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PVLA's short-term assets ($263.23M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PVLA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PVLA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$10.9M
Investing
-$55.4M
Financing
$214.7M
PVLA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PVLA vs Biotech Stocks
Palvella Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.